Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Mechanical flow disruption" describes a physical or physiological event where mechanical forces—often from fluid shear stress or deformation—cause *plasma membrane disruptions* (PMD) in cells. These disruptions permit the temporary flux of molecules across the plasma membrane, initiating intracellular signaling cascades important for mechanotransduction, tissue adaptation, and paracrine signaling. For example, in various tissues (cardiac and skeletal muscle, endothelial cells, epithelial cells), PMD can lead to the release of secondary messengers such as ATP and nitric oxide and transient activation of gene expression (e.g., c-fos), influencing downstream processes like repair, remodeling, or disease initiation[1][2]. While essential for normal adaptation, chronic or excessive mechanical disruption is implicated in pathologies such as cardiovascular disease, fibrosis, and cancer[5][6].\nMechanically induced plasma membrane disruptions are rapidly repaired by cells, and the repair process is itself regulated by the magnitude and frequency of the mechanical challenge[1]. "Mechanical flow disruption" is therefore a mechanistic concept, not a druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mechanical flow disruption.